Peripheral Helper T-cells in Common Variable ImmunoDeficiency

NCT ID: NCT07255157

Last Updated: 2025-12-10

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-12-31
• Study Completion Date: 2027-12-31

Brief Summary

The aim is to determine whether whether Tph could support non-infectious complications through providing help to pathological B-cells.

Detailed Description

Common variable immunodeficiency (CVID), the most common symptomatic primary immunodeficiency in adults, can associate recurrent infections with severe non-infectious complications. Unfortunately, there is still no absolute biomarker predicting which CVID patient will develop non-infectious complications. Thus, novel biomarkers which could help refining CVID patient prognosis require further investigations. Moreover, the immune mechanisms driving non-infectious complications remain elusive. Therefore, further insight into CVID pathophysiology is needed to discover new treatments for CVID patients with non-infectious complications (CVIDc). The preliminary results show that CVIDc patients have an increase of circulating peripheral helper T-cells (Tph) , in comparison with patients with infectious manifestations only (CVIDi) and healthy individuals (HI). Recently described, Tph express CXCR3, help memory B-cells and are found in inflamed tissues in auto-immune diseases. They represent a major reservoir of auto-reactive T-cells, suggesting that Tph are key to drive auto-immune processes. Some authors hypothesized that Tph can help atypical memory B-cells (ABCs), a B-cell subset which is involved in auto-immune disease pathophysiology and which is also expanded in CVIDc patients. The investigators observed that CXCR3+ cells were increased in the spleen of CVIDc patients in comparison with non-CVID controls. These CXCR3+ cells could correspond to Tph supporting extra-follicular reaction and then B-cell tolerance loss. The hypothesis is that alterations in T-B cell collaboration leads to the amplification of Tph in CVID patients. Tph could support non-infectious complications in target tissues through providing help to pathological B-cells such as ABCs. Using peripheral blood from CVIDc/CVIDi patients and HI, the investigators will determine whether Tph support pathological B cell activation in CVIDc patients using T-B co-cultures. Patients will be included during their routine follow-up, for one day.

Conditions

Common Variable Immunodeficiency

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Common variable immunodeficiency

Group Type: EXPERIMENTAL

blood sample

Intervention Type: OTHER

48 ml whole blood for Peripheral blood mononuclear cell (PBMC) and serum isolation

Controls

Healthy controls

Group Type: ACTIVE_COMPARATOR

blood sample

Intervention Type: OTHER

48 ml whole blood for Peripheral blood mononuclear cell (PBMC) and serum isolation

Interventions

blood sample

48 ml whole blood for Peripheral blood mononuclear cell (PBMC) and serum isolation

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Male or female;
• Age ≥ 18 years;
• Standard criteria will be applied to diagnose CVID, specifically requiring: 1) low serum IgG level <5 g/L, combined with low IgM- and/or IgA-isotype concentrations <0.4 g/L or <0.7 g/L, respectively; 2) poor antibody responses to immunization or infection; and 3) exclusion of other defined forms of secondary hypogammaglobulinemias. Patients meeting the definitional criteria for CVID will be included, regardless of the duration of the disease or the treatment received (gammaglobulins substitution or not);
• Being affiliated to health insurance;
• Willing to participate and to sign informed consent.

Exclusion Criteria

• Patients on corticosteroids and/or immunosuppressants;
• Patients with a primary immunodeficiency genetically characterized, such as Bruton disease our HyperIgM syndrome;
• Patients with an active chronic infection;
• Pregnant or breastfeeding women;
• Persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University Hospital, Bordeaux

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jean-François VIALLARD, Prof

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Bordeaux

Jonathan VISENTIN, Prof

Role: STUDY_DIRECTOR

University Hospital, Bordeaux

Locations

CHU de Bordeaux - service de médecine interne

Pessac, , France

Countries

France

Central Contacts

Jean-François VIALLARD, Prof

Role: CONTACT

jean-françois.viallard@chu-bordeaux.fr

(0)5.57.65.64.83 ext. +33

Carine LOPEZ

Role: CONTACT

carine.lopez@chu-bordeaux.fr

(0)5.24.54.91.32 ext. +33

Facility Contacts

Jean-François VIALLARD, Prof

Role: primary

jean-françois.viallard@chu-bordeaux.fr

(0)5.57.65.64.83 ext. +33

Carine LOPEZ

Role: backup

carine.lopez@chu-bordeaux.fr

(0)5.24.54.91.32 ext. +33

Other Identifiers

CHUBX 2025/037

Identifier Type: -

Identifier Source: org_study_id